Pharmacology of Aminophylline for Acute Kidney Injury in Neonates

Stopped early

Conditions studied: Acute Kidney Injury

In brief

Acute kidney injury (AKI) in critically ill neonates is common and associated with significant morbidity and mortality. No targeted therapeutic treatment strategies have been established for AKI in neonates. Within a clinical pharmacokinetic and pharmacodynamic conceptual framework, this project will examine the medication aminophylline as a potential treatment approach for AKI.

Key facts

Study ID

NCT02276170

Run by

Stanford University

People needed

9

Starts

2014-10-01

Expected to finish

2018-08-01

Last updated by the study team

2019-09-19

Who can join

Age: any, up to 0. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Neonate < 3 months post natal age
• Diagnosed with acute kidney injury (AKI)
• Receiving aminophylline for AKI treatment as per local standard of care.

You may not qualify if…

• Presence of anatomical renal anomaly based on postnatal evaluation of the patient (hydronephrosis, multicystic kidney, renal agenesis, renal dysplasia, polycystic kidney, or obstructive uropathy)
• Patient on renal replacement therapy
• Major genetic abnormalities (trisomy 13, 18 or 21).

Where it is running

• Lucile Packard Children's Hospital Stanford — Palo Alto, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.